afdx 116 has been researched along with soman in 1 studies
| Studies (afdx 116) | Trials (afdx 116) | Recent Studies (post-2010) (afdx 116) | Studies (soman) | Trials (soman) | Recent Studies (post-2010) (soman) |
|---|---|---|---|---|---|
| 367 | 1 | 24 | 1,391 | 4 | 257 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albuquerque, EX; Aracava, Y; Castro, NG; Fawcett, WP; Pereira, EF; Randall, WR; Santos, MD | 1 |
1 other study(ies) available for afdx 116 and soman
| Article | Year |
|---|---|
Low concentrations of pyridostigmine prevent soman-induced inhibition of GABAergic transmission in the central nervous system: involvement of muscarinic receptors.
Topics: Animals; Atropine; Central Nervous System; Cholinesterase Inhibitors; Cholinesterases; Electric Stimulation; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Hippocampus; In Vitro Techniques; Membrane Potentials; Muscarinic Antagonists; Neurons; Patch-Clamp Techniques; Piperidines; Pirenzepine; Pyramidal Cells; Pyridostigmine Bromide; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Receptors, Muscarinic; Receptors, Nicotinic; Soman; Synaptic Transmission | 2003 |